Last reviewed · How we verify
Placebo of KW21052
Placebo of KW21052 is a Small molecule drug developed by KunWha Pharmaceutical Co., Ltd.. It is currently in Phase 3 development.
This is a placebo control and contains no active pharmaceutical ingredient.
At a glance
| Generic name | Placebo of KW21052 |
|---|---|
| Sponsor | KunWha Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo formulation for KW21052, this product is inert and serves as a control comparator in clinical trials. It is designed to match the appearance and administration route of the active drug to maintain blinding in phase 3 studies.
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of KW21052 Compared to Lyrica in the Diabetic Patients With Neuropathic Pain (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of KW21052 CI brief — competitive landscape report
- Placebo of KW21052 updates RSS · CI watch RSS
- KunWha Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about Placebo of KW21052
What is Placebo of KW21052?
How does Placebo of KW21052 work?
Who makes Placebo of KW21052?
What development phase is Placebo of KW21052 in?
Related
- Manufacturer: KunWha Pharmaceutical Co., Ltd. — full pipeline
- Compare: Placebo of KW21052 vs similar drugs
- Pricing: Placebo of KW21052 cost, discount & access